Chairman Chey Tae-won Discusses Global Cooperation in Chongqing, China
September 10, 2019
August 26 | Chairman Chey Tae-won discusses global cooperation in Chongqing, China
Chairman Chey Tae-won was invited to be the keynote speaker of ‘2019 Smart China Expo’ held in Chongqing, China from August 26 to 29. Chairman Chey stated, “Smart technology innovation can maximize social value creation and boost up sustainability,” and suggested that “Chongqing City adopts the environmental industry of the future as a new agenda in addition to the conventional focus on smart technology advancement.” Chairman Chey also visited the exhibition booths of SK hynix and other global IT enterprises and discussed potential expansion of business partnership between SK and Chongqing City and smart technology-enabled new collaboration strategy with the representatives of Chongqing City Government including Party Secretary Chen Min’er and Mayor Tang Liangzhi. The Smart China Expo is a government-organized expo held since last year by the Chinese Ministry of Science and Technology, the Ministry of Industry and Information Technology, and the Academy of Science to promote Chongqing as the hub of big data and smart technologies in China.
August 30 | SK holdings incorporates an integrated pharmaceutical production entity
SK holdings decided to incorporate an integrated CMO entity ‘SK pharmteco’ in Sacramento, California, United States, in its board meeting held on August 30 to integrate the operations of SK biotech Korea, SK biotech Ireland, and AMPAC in the United States. SK holdings will invest its holding of SK biotech shares and other assets transferred from SK biotech in SK pharmteco; and SK biotech Korea, SK biotech Ireland and AMPAC will become 100%-owned subsidiaries of SK pharmteco and grandchild subsidiaries of SK holdings. SK pharmteco, to set sail next January, will be incorporated to simplify the distributed governance of pharmaceutical production business thus maximizing synergy and efficiency. In addition, their marketing operations will be integrated under a single brand to boost up brand awareness in the global market and optimize operations of each regional CMO.
August 26 | US Rep. John Moolenaar visited the Michigan plant of SK global chemical
US Representative John Moolenaar visited SK Saran Americas (SKSA hereinafter) on August 26 which is one of the iconic global packaging worksites of SK global chemical. Rep. John Moolenaar did a tour around the plant with CEO Kim Jong-hyeon of the US subsidiary of SK global chemical, and SKSA plant director Stephen Persyn, among others and discussed future investment/employment plans as well as mutual cooperation strategies including the need for support from the state government. On site, Rep. John Moolenaar said, “I am so pleased to meet SKSA people in the production site of packaging materials used widely around the world including the United States,” and added, “I will continue to work on promoting a business environment friendly to the workers and corporations of the State of Michigan.” CEO Kim replied, “SK will study and implement further strategies to deliver greater values to customers and local communities from a long-term perspective.”
September 2 | SK plasma ventures into the global market with its proprietary blood product technology
SK plasma concluded a third-party business outsourcing MOU on September 2 with the Indonesian state-run pharmaceutical company Bio Farma and the Indonesian Red Cross Society for blood products production outsourcing and technology transfer. This marks the first occasion in which a Korean blood products-specialized corporation exports related technologies to Indonesia. The Korea-Indonesia healthcare cooperation conference held in Jakarta, Indonesia provided momentum for the MOU signing ceremony. Under the MOU, SK plasma’s finished products will be registered and imported to Indonesia; Indonesian blood plasma raw material will be used in outsourcing production in SK plasma Andong plant; and SK plasma will transfer technologies and build Bio Farma derivatives plant. SK plasma plans to leverage this MOU as a stepping stone into the global market by ensuring that the excellence of Korean technology is recognized in the global market.